Sanofi Consumer Healthcare India Limited delivered impressive financial performance in Q1'26, demonstrating strong growth across multiple business segments. The company's Board of Directors approved the unaudited financial results for the quarter ended 31st March 2026 during their meeting held on 28th April 2026.

Financial Performance Overview

The company's financial metrics for Q1'26 showed robust year-on-year growth across key parameters:

Business Segment Performance

The company's domestic operations showed strong momentum with 15.5% growth in domestic sales. This growth was primarily driven by the successful relaunch of recalled products back to the market, indicating effective operational recovery and market response.

Export sales demonstrated exceptional performance with 144% growth, though the company attributed this significant increase to a low base effect from the previous year. This substantial export growth contributed meaningfully to the overall revenue performance for the quarter.

Management Commentary

Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, highlighted the company's disciplined execution strategy. He emphasized that the domestic business outpaced market performance, delivering both market share gains and volume growth. Bakshi noted the company's commitment to simplifying self-care and making it more accessible and effective for consumers, guided by science and driven by purpose.

Company Background

Sanofi Consumer Healthcare India Limited operates as an independent entity following its demerger from Sanofi India Limited on 1st June 2024. The company focuses exclusively on the Consumer Healthcare sector with a portfolio spanning multiple therapeutic areas:

• Allergy Care • Digestive Wellness • Pain Care • Multivitamins

The company's key brands include Allegra®, DePURA®, Avil®, and Combiflam®. With its agile business model and strong brand portfolio, the company positions itself as one of the leading players in India's consumer healthcare market, leveraging global experience to enhance customer wellbeing through accessible self-care solutions.

Sanofi Consumer Healthcare India Limited announced the results of its postal ballot conducted under Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on April 23, 2026. The postal ballot sought member approval for four ordinary resolutions related to related party transactions and remuneration matters. Mr. Omkar Dindorkar, Partner at M/s. MMJB & Associates LLP, Practicing Company Secretaries, served as the Scrutinizer for the process and submitted his report on April 23, 2026.

The postal ballot voting period commenced on March 24, 2026, at 9:00 a.m. IST and concluded on April 22, 2026, at 5:00 p.m. IST. The total number of shareholders on the record date stood at 50,742. National Securities Depository Limited (NSDL) provided the remote e-voting facility for the postal ballot process.

All four resolutions were approved with an overwhelming majority by the members of the company. The detailed voting results are as follows:

The total number of shares held across all categories was 23,030,622. For the resolutions related to related party transactions, Promoter and Promoter Group did not vote as per Regulation 23(4) of Listing Regulations, which prohibits related parties from voting on such resolutions. Public Institutions and Public Non-Institutions participated actively in the voting process.

For the remuneration-related resolutions, Promoter and Promoter Group cast 16,414,217 votes, all in favour. Public Institutions cast 4,490,436 votes with 100% support for the Non-Executive Director remuneration resolution and 99.9334% support for the Managing Director remuneration amendment. Public Non-Institutions cast 21,899 votes for the Non-Executive Director resolution and 21,879 votes for the Managing Director resolution.

The Scrutinizer confirmed that there were no invalid votes, abstained votes, or less votes cast on the above resolutions. The resolutions were passed with the requisite majority. The company submitted the voting results signed by the Company Secretary, along with the Scrutinizer's Report dated April 23, 2026, to both BSE Limited and National Stock Exchange of India Limited. The company's scrip code on BSE is 544250 and the trading symbol on NSE is SANOFICONR.